2025年4月2日 周三
首页 > 按月查看>2021年第12月 >1099-1104
PDF 导出
低密度脂蛋白受体相关蛋白6的功能及其在疾病研究中的进展
作者:
作者单位:

(1.南华大学衡阳医学院,湖南省衡阳市 421001;2.中南大学生命科学学院,湖南省长沙市 410000;3.南华大学衡阳医学院外科学总论教研室,湖南省衡阳市 421001)

作者简介:

付世青,硕士研究生,研究方向为神经退行性疾病的发病机制,E-mail为1436445126@qq.com。

基金项目:

湖南省教育厅基金项目(17C1396)；国家级大学生创新创业训练计划项目(201710555009)


The research progress on function of low density lipoprotein receptor-related protein 6 and its related diseases
Author:
Affiliation:

1.Hengyang Medical College, University of South China, Hengyang, Hunan 421001, China;2.School of Life Sciences, Central South University, Changsha, Hunan 410000, China;3.Department of General Surgery, Hengyang Medical College, University of South China, Hengyang, Hunan 421001, China)

  • 摘要
    • | |
  • 访问统计
    • |
  • 参考文献
    • |
  • 相似文献
    • | |
    摘要:

    低密度脂蛋白受体相关蛋白6是经典Wnt信号通路的重要受体蛋白之一。该蛋白编码基因的突变与人类多种疾病相关,包括代谢综合征、肿瘤、阿尔兹海默症以及骨质疏松症等。低密度脂蛋白受体相关蛋白6的突变基因形式在临床诊断中亦具有重要的指导意义。本文将围绕低密度脂蛋白受体相关蛋白6的功能及其相关疾病作一综述。

    Abstract:

    The low density lipoprotein receptor-related protein 6 (LRP6) is one of the important receptor proteins that perform the canonical Wnt/β-catenin pathway. Mutations in the protein are often associated with a variety of human diseases, including metabolic syndrome, tumor, Alzheimer's disease and osteoporosis. The mutation of low-density lipoprotein receptor-related protein 6 will have important guiding significance in the clinical diagnosis. In this paper, the function of low-density lipoprotein receptor-related protein 6 and the occurrence and development of related diseases will be summarized to provide useful resources for future research.

    参考文献
    [1] BOURHIS E, TAM C, FRANKE Y, et al.Reconstitution of a frizzled8.Wnt3a.LRP6 signaling complex reveals multiple Wnt and Dkk1 binding sites on LRP6.J Biol Chem, 0,5(12):9172-9179.
    [2] CHEN S, BUBECK D, MACDONALD B T, et al.Structural and functional studies of LRP6 ectodomain reveal a platform for Wnt signaling.Dev Cell, 1,1(5):848-861.
    [3] CHEN J, YAN H, REN D N, et al.LRP6 dimerization through its LDLR domain is required for robust canonical Wnt pathway activation.Cell Signal, 4,6(5):1068-1074.
    [4] KLAUS A, BIRCHMEIER W.Wnt signalling and its impact on development and cancer.Nat Rev Cancer, 8,8(5):387-398.
    [5] BILIC J, HUANG Y L, DAVIDSON G, et al.Wnt induces LRP6 signalosomes and promotes dishevelled-dependent LRP6 phosphorylation.Science, 7,6(5831):1619-1622.
    [6] NUSSE R, CLEVERS H.Wnt/β-Catenin signaling, disease, and emerging therapeutic modalities.Cell, 7,9(6):985-999.
    [7] BRENNAN K, GONZALEZ-SANCHO J M, CASTELO-SOCCIO L A, et al.Truncated mutants of the putative Wnt receptor LRP6/Arrow can stabilize beta-catenin independently of frizzled proteins.Oncogene, 4,3(28):4873-4884.
    [8] TAMAI K, SEMENOV M, KATO Y, et al.LDL-receptor-related proteins in Wnt signal transduction.Nature, 0,7(683):530-535.
    [9] BUGTER J M, FENDERICO N, MAURICE M M.Mutations and mechanisms of WNT pathway tumour suppressors in cancer.Nat Rev Cancer, 1,1(1):5-21.
    [10] THOMPSON J J, SHORT S P, PARANG B, et al.Blood vessel epicardial substance (BVES) reduces LRP6 receptor and cytoplasmic-catenin levels to modulate Wnt signaling and intestinal homeostasis.Carcinogenesis, 9,0(9):1086-1098.
    [11] STEINBERGER J, DANIELS S R, ECKEL R H, et al.Progress and challenges in metabolic syndrome in children and adolescents:a scientific statement from the American Heart Association Atherosclerosis,Hypertension,and Obesity in the Young Committee of the Council on Cardiovascular Disease in the Young;Council on Cardiovascular Nursing;and Council on Nutrition,Physical Activity,and Metabolism.Circulation, 9,9(4):628-647.
    [12] MANI A, RADHAKRISHNAN J, WANG H, et al.LRP6 mutation in a family with early coronary disease and metabolic risk factors.Science, 7,5(5816):1278-1282.
    [13] SINGH R, DE AGUIAR R B, NAIK S, et al.LRP6 enhances glucose metabolism by promoting TCF7L2-dependent insulin receptor expression and IGF receptor stabilization in humans.Cell Metab, 3,7(2):197-209.
    [14] GO G W, SRIVASTAVA R, HERNANDEZ-ONO A A, et al.The combined hyperlipidemia caused by impaired Wnt-LRP6 signaling is reversed by Wnt3a rescue.Cell Metab, 4,9(2):209-220.
    [15] 张婵娟, 覃丽.Wnt信号通路介导胆固醇逆向转运与炎症应答的交互作用.中国动脉硬化杂志, 8,6(8):843-850.
    [16] CHENG S L, RAMACHANDRAN B, BEHRMANN A, et al.Vascular smooth muscle LRP6 limits arteriosclerotic calcification in diabetic LDLR－/－ mice by restraining noncanonical Wnt signals.Circ Res, 5,7(2):142-156.
    [17] 耿武军, 陈成宇, 张民远, 等.Wnt/β-catenin信号通路通过下调自噬改善大鼠脑缺血再灌注损伤.中国动脉硬化杂志, 8,6(3):222-226.
    [18] WANG S, SONG K, SRIVASTAVA R, et al.Nonalcoholic fatty liver disease induced by noncanonical Wnt and its rescue by Wnt3a.FASEB J, 5,9(8):3436-3445.
    [19] SARZANI R, SALVI F, BORDICCHIA M, et al.Carotid artery atherosclerosis in hypertensive patients with a functional LDL receptor-related protein 6 gene variant.Nutr Metab Cardiovasc Dis, 1,1(2):150-156.
    [20] LIU Y, NEOGI A, MANI A.The role of Wnt signalling in development of coronary artery disease and its risk factors.Open Biol, 0,0(10):200128.
    [21] RAISCH J, CT-BIRON A, RIVARD N.A role for the WNT Co-Receptor LRP6 in pathogenesis and therapy of epithelial cancers.Cancers (Basel), 9,1(8):1162.
    [22] RISMANI E, FAZELI M S, MAHMOODZADEH H, et al.Pattern of LRP6 gene expression in tumoral tissues of colorectal cancer.Cancer Biomark, 7,9(2):151-159.
    [23] XIAO J, XING F, LIU Y, et al.Garlic-derived compound S-allylmercaptocysteine inhibits hepatocarcinogenesis through targeting LRP6/Wnt pathway.Acta Pharm Sin B, 8,8(4):575-586.
    [24] YAO Q, AN Y, HOU W, et al.LRP6 promotes invasion and metastasis of colorectal cancer through cytoskeleton dynamics.Oncotarget, 7,8(65):109632-109645.
    [25] JIA Q, BU Y, WANG Z, et al.Maintenance of stemness is associated with the interation of LRP6 and heparin-binding protein CCN2 autocrined by hepatocellular carcinoma.J Exp Clin Cancer Res, 7,6(1):117.
    [26] MAO X, TEY S K, KO F, et al.C-terminal truncated HBx protein activates caveolin-1/LRP6/β-catenin/FRMD5 Axis in promoting hepatocarcinogenesis.Cancer Lett, 9,4:60-69.
    [27] ZHOU L, WANG Z, YU S, et al.CDDO-Me elicits anti-breast cancer activity by targeting LRP6 and FZD7 receptor complex.J Pharmacol Exp Ther, 0,3(1):149-159.
    [28] GARG B, GIRI B, MAJUMDER K, et al.Modulation of post-translational modifications in β-catenin and LRP6 inhibits Wnt signaling pathway in pancreatic cancer.Cancer Lett, 7,8:64-72.
    [29] DENG D, ZHANG Y, BAO W, et al.Low-density lipoprotein receptor-related protein 6 (LRP6) rs10845498 polymorphism is associated with a decreased risk of non-small cell lung cancer.Int J Med Sci, 4,1(7):685-690.
    [30] PIERZYNSKI J A, HILDEBRANDT M, KAMAT A M, et al.Genetic variants in the Wnt/β-Catenin signaling pathway as indicators of bladder cancer risk.J Urol, 5,4(6):1771-1776.
    [31] DE V R, HAHN M M, WEREN R D, et al.Identification of novel candidate genes for early-onset colorectal cancer susceptibility.PLoS Genet, 6,2(2):e1005880.
    [32] 刘丽, 龙鼎新.Wnt信号通路在神经系统发育中的作用研究进展.中南医学科学杂志, 2017(3):303-306.
    [33] DE FERRARI G V, PAPASSOTIROPOULOS A, BIECHELE T, et al.Common genetic variation within the low-density lipoprotein receptor-related protein 6 and late-onset Alzheimer's disease.Proc Natl Acad Sci U S A, 7,4(22):9434-9439.
    [34] ALI A, ALI A, AHMAD W, et al.Deciphering the role of WNT signaling in metabolic syndrome-linked Alzheimer's disease.Mol Neurobiol, 0,7(1):302-314.
    [35] LIU C C, TSAI C W, DEAK F, et al.Deficiency in LRP6-mediated Wnt signaling contributes to synaptic abnormalities and amyloid pathology in Alzheimer's disease.Neuron, 4,4(1):63-77.
    [36] TAN L, XING A, ZHAO D L, et al.Strong association of lipid metabolism related microRNA binding sites polymorphisms with the risk of late onset Alzheimer's disease.Curr Neurovasc Res, 7,4(1):3-10.
    [37] LI H, XIAO Z, QUARLES L D, et al.Osteoporosis:mechanism, molecular target and current status on drug development.Curr Med Chem, 1,8(8):1489-1507.
    [38] RIDDLE R C, DIEGEL C R, LESLIE J M, et al.LRP5 and LRP6 exert overlapping functions in osteoblasts during postnatal bone acquisition.PLoS One, 3,8(5):e63323.
    [39] SCHUMACHER C A, JOINER D M, LESS K D, et al.Characterization of genetically engineered mouse models carrying Col2a1-cre-induced deletions of LRP5 and/or LRP6.Bone Res, 6,4:15042.
    [40] STRZNICKEL J, ROLVIEN T, DELSMANN A, et al.Clinical phenotype and relevance of LRP5 and LRP6 variants in patients with early-onset osteoporosis (EOOP).J Bone Miner Res, 1,6(2):271-282.
    引证文献
引用本文

付世青,谭洁琼,王芳.低密度脂蛋白受体相关蛋白6的功能及其在疾病研究中的进展[J].中国动脉硬化杂志,2021,29(12):1099~1104.

复制
分享
文章指标
  • 点击次数:489
  • 下载次数: 1192
历史
  • 收稿日期:2021-05-21
  • 最后修改日期:2021-06-27
  • 在线发布日期: 2021-11-24

您是本站第 4758136 访问者

邮编：421001 传真：0734-8160523

电话：0734-8160765 E-mail：dmzzbjb@163.net

中国动脉硬化杂志 ® 2025 网站版权所有